John Madrigal

773 total citations
6 papers, 68 citations indexed

About

John Madrigal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, John Madrigal has authored 6 papers receiving a total of 68 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Cancer Research. Recurrent topics in John Madrigal's work include Cancer Immunotherapy and Biomarkers (5 papers), Lung Cancer Treatments and Mutations (3 papers) and Cancer Genomics and Diagnostics (2 papers). John Madrigal is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Lung Cancer Treatments and Mutations (3 papers) and Cancer Genomics and Diagnostics (2 papers). John Madrigal collaborates with scholars based in United States, Austria and United Kingdom. John Madrigal's co-authors include Amy L. Cummings, Aaron Lisberg, James Carroll, Edward B. Garon, Hira Rizvi, Siwen Hu‐Lieskovan, Jaklin Gukasyan, Dennis J. Slamon, I. Peter Shintaku and Jesse M. Zaretsky and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Thoracic Oncology.

In The Last Decade

John Madrigal

5 papers receiving 68 citations

Peers

John Madrigal

ONCOL

PRM

IMMUN

CR

SURGE

Livia Andrade United States

Eveline Cuypere Belgium

A.A. Luczak Denmark

Jaklin Gukasyan United States

Mitchell Denker United States

Sarah Warren United States

Ovid Trifan United States

Liyi Jia United States

David Gutiérrez Abad Spain

Blanca Ledezma United States

Livia Andrade United States

John Madrigal

69 ×1.1

ONCOL

31 ×1.0

PRM

21 ×0.7

IMMUN

24 ×2.0

CR

1 ×0.5

SURGE

Citations per year, relative to John Madrigal John Madrigal (= 1×) peers Livia Andrade

Countries citing papers authored by John Madrigal

Since Specialization

Citations

This map shows the geographic impact of John Madrigal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Madrigal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Madrigal more than expected).

Fields of papers citing papers by John Madrigal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Madrigal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Madrigal. The network helps show where John Madrigal may publish in the future.

Co-authorship network of co-authors of John Madrigal

This figure shows the co-authorship network connecting the top 25 collaborators of John Madrigal. A scholar is included among the top collaborators of John Madrigal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Madrigal. John Madrigal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Hu‐Lieskovan, Siwen, Aaron Lisberg, Jesse M. Zaretsky, et al.. (2019). Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(16). 5061–5068. 56 indexed citations

2.

Rochigneux, Philippe, Aaron Lisberg, Anne-Sophie Chrétien, et al.. (2019). P1.04-33 Deep Phenotyping of Immune Populations Reveals Baseline Predictors of Pembrolizumab Efficacy in NSCLC on KEYNOTE-001. Journal of Thoracic Oncology. 14(10). S452–S453. 2 indexed citations

3.

Lisberg, Aaron, Amy L. Cummings, Jonathan W. Goldman, et al.. (2018). A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.. Journal of Clinical Oncology. 36(15_suppl). 9014–9014. 5 indexed citations

4.

Lisberg, Aaron, Krikor Bornazyan, John Madrigal, et al.. (2017). P2.07-038 Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA. Journal of Thoracic Oncology. 12(11). S2430–S2430. 1 indexed citations

5.

Lisberg, Aaron, J.S. Hunt, Nicholas Reese, et al.. (2017). MA 02.07 A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC. Journal of Thoracic Oncology. 12(11). S1805–S1805. 4 indexed citations

6.

Peña, Hugo De La & John Madrigal. (2006). Inmunoterapia celular contra el cáncer. 5(3). 61–64.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact